Oaktree Specialty Lending Corporation Schedules Third Fiscal Quarter Earnings Conference Call for August 5, 2025 11:00 a.m. Eastern Time / 8:00 a.m. Pacific Time LOS ANGELES, CA, July 02, 2025 (GLOBE NEWSWIRE) -- Oaktree Specialty Lending Corporation (NASDAQ:OCSL) (“Oaktree Specialty Lending” or the “Company”) today announced that it will report its financial results for the third fiscal quarter ended June 30, 2025 before the opening of the Nasdaq Global Select Market on Tuesday, August 5, 2025. Management will host a conference call to discuss the results on the same day at 11:00 a.m. ...
A director at Novagold Resources Inc bought 10,000 shares at 4.100USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
NBT Bancorp Inc. Announces Date of Second Quarter Conference Call NORWICH, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- NBT Bancorp Inc. (“NBT” or the “Company”) (NASDAQ: NBTB) will release details of its financial results for the second quarter 2025 on Monday, July 28, 2025, following the market close. The Company will host a conference call at 10:00 a.m. (Eastern) Tuesday, July 29, 2025, to review these results. The audio webcast link, along with the corresponding presentation slides, will be available on the Company’s Event Calendar page at prior to the beginning of the conference call. T...
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved for PMN, a rare immune-mediated disease affecting the kidneys with an estimated prevalence of ~36k patients in the U.S.1Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-med...
New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWI...
Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 27th June 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication. Top three shareholders are taken from the websit...
Minerals Technologies Inc. Announces Second Quarter 2025 Conference Call on July 25, 2025 NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI”) announced today that it will release results for its second quarter ended June 29, 2025, on Thursday, July 24, 2025, after the market close. MTI will host a conference call on Friday, July 25, 2025, at 11 a.m. Eastern Time (ET) to discuss these results. Investors and other interested parties can access the webcast and presentation materials on MTI’s Investor Relations and pre-register for the webcast at any t...
NOVAGOLD Files Second Quarter 2025 Report Announced a pivotal transaction with Paulson Advisers – NOVAGOLD acquired an additional 10% economic interest increasing its stake to 60% in Donlin Gold LLC to advance the project to the next phase of an updated Feasibility Study.Strengthened the Company’s treasury by completing a public equity offering and a private placement of 65 million shares, resulting in approximately $234 million in net proceeds.Advanced the Donlin Gold 15,000-meter drill program now focused on converting and expanding reserves and resources. VANCOUVER, British Columbia, Ju...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.